# Study to Evaluate Efficacy, Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder Without Psychiatric Comorbidity

> **NCT02464046** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 28 (actual)

## Conditions studied

- Insomnia

## Interventions

- **DRUG:** JNJ-42847922
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02464046
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-27
- **Primary completion:** 2015-12-02
- **Final completion:** 2015-12-02
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02464046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02464046, "Study to Evaluate Efficacy, Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder Without Psychiatric Comorbidity". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT02464046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*